Myelofibrosis: Mechanisms, Pathophysiology, and Extramedullary Hematopoiesis
Myelofibrosis is a clonal neoplastic disorder of hematopoiesis—the biological process responsible for the formation of blood cellular components. As a member of the myeloproliferative disorders, it is characterized by the bone marrow producing an excess of cells at certain stages of development. This condition fundamentally alters the architecture of the bone marrow, leading to systemic complications that affect the entire blood-forming system.
The Mechanism of Bone Marrow Fibrosis
The progression of myelofibrosis begins with an abnormal hematopoietic cell clone, particularly involving megakaryocytes (large bone marrow cells that produce platelets). These abnormal cells release cytokines, such as fibroblast growth factor, which trigger a secondary reaction in the marrow. This process leads to collagen fibrosis, where the normal hematopoietic tissue is replaced by connective tissue.
It is important to note that while fibroblasts proliferate and deposit collagen, the fibroblasts themselves are not part of the abnormal neoplastic clone; their activity is a secondary response to the signals sent by the abnormal hematopoietic cells.
As the hematopoietic tissue decreases, the body's ability to generate new blood cells is severely impaired. This results in pancytopenia, a clinical state defined by a shortage of all three types of blood cells: red cells, white cells, and platelets.
[ไม่มีภาพประกอบ]Extramedullary Hematopoiesis and Organ Enlargement
In primary myelofibrosis, the progressive scarring of the bone marrow forces the hematopoietic cells to migrate to other areas of the body to maintain blood production. This phenomenon is known as extramedullary hematopoiesis.
The primary sites for this displaced blood cell formation are the spleen and the liver. This migration leads to significant organ enlargement:
- Splenomegaly: The enlargement of the spleen. This not only occurs due to the production of blood cells but also contributes to pancytopenia, specifically anemia and thrombocytopenia (low platelet count).
- Hepatomegaly: The enlargement of the liver.
Another consequence of this displaced production is poikilocytosis, which refers to the presence of abnormally shaped red blood cells in the bloodstream.
Secondary Myelofibrosis and Evolution
Myelofibrosis does not always occur as a primary condition. It can develop as a late complication of other myeloproliferative disorders, such as polycythemia vera or, less frequently, essential thrombocythemia. In these instances, the condition arises from the somatic evolution of the original abnormal hematopoietic stem cell clone.
Research indicates that in some cases, the transition to myelofibrosis following these disorders may be accelerated by the use of the oral chemotherapy medication hydroxyurea.
Sites of Hematopoiesis and Cellular Changes
The spleen serves as the principal site for extramedullary hematopoiesis and can become massively enlarged, sometimes reaching weights of up to 4000 g. This extreme size can lead to multiple subcapsular infarcts, where tissue death occurs due to an interrupted oxygen supply.
On a cellular level, the spleen in these patients contains granulocyte precursors, red blood cell precursors, and a prominent number of bizarrely shaped megakaryocytes. While the liver often shows moderate enlargement with foci of hematopoiesis, lymph nodes may also contain these foci, though usually not enough to cause visible enlargement. In rare reports, hematopoiesis has occurred in the lungs, which is associated with pulmonary artery hypertension.
Within the bone marrow itself, typical cases show a hypercellular environment that is diffusely fibrotic, with dysplastic megakaryocytes present throughout both early and late stages of the disease.
[ไม่มีภาพประกอบ]| Feature | Description/Effect |
|---|---|
| Primary Cause | Clonal neoplastic disorder of hematopoiesis |
| Key Driver | Cytokines (e.g., fibroblast growth factor) from megakaryocytes |
| Marrow Change | Replacement of hematopoietic tissue with collagen fibrosis |
| Blood Result | Pancytopenia (shortage of all blood cell types) |
| Alternative Sites | Spleen (primary), Liver, Lymph nodes, Lungs |
| Organ Effects | Splenomegaly, Hepatomegaly, Subcapsular infarcts |
Key Facts
- Myelofibrosis involves the replacement of bone marrow with connective tissue via collagen fibrosis.
- The fibrosis is a secondary phenomenon triggered by abnormal megakaryocytes, not by the fibroblasts themselves.
- Extramedullary hematopoiesis occurs when blood cell production shifts to the spleen and liver.
- The spleen can enlarge up to 4000 g, potentially leading to tissue death (infarcts).
- It can evolve from other disorders like polycythemia vera or essential thrombocythemia.
- Poikilocytosis (abnormally shaped red blood cells) is a common complication.
Frequently Asked Questions
What is the difference between primary and secondary myelofibrosis?
Primary myelofibrosis occurs as a standalone disorder of the hematopoietic stem cells. Secondary myelofibrosis develops as a late complication of other myeloproliferative disorders, such as polycythemia vera or essential thrombocythemia, through somatic evolution of the cell clone.
Why does the spleen enlarge in myelofibrosis?
The spleen enlarges (splenomegaly) because it becomes a primary site for extramedullary hematopoiesis. As the bone marrow becomes fibrotic and unable to produce blood cells, the spleen takes over the production of red cells, granulocytes, and megakaryocytes.
What is pancytopenia and why does it happen?
Pancytopenia is a deficiency of all three blood cell types: red blood cells, white blood cells, and platelets. It occurs because the collagen fibrosis in the bone marrow destroys the tissue necessary for normal blood cell generation.
Can medications influence the development of myelofibrosis?
Yes, in patients who already have other myeloproliferative disorders, the development of myelofibrosis may be accelerated by the oral chemotherapy drug hydroxyurea.
What are subcapsular infarcts in the spleen?
Subcapsular infarcts are areas of partial or complete tissue death within the spleen. They occur when the spleen becomes so massively enlarged that the oxygen supply to the tissue is interrupted.